Quantcast
Last updated on April 20, 2014 at 13:20 EDT

Latest Antibody Stories

2014-01-07 08:32:18

SAN FRANCISCO, Jan. 7, 2014 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced that it has entered into a collaboration agreement with Memorial Sloan-Kettering Cancer Center to use Sutro's proprietary cell-free protein synthesis technology to produce bispecific antibodies that were discovered by Memorial Sloan-Kettering for the...

2014-01-06 10:17:40

Earlier amyloid-beta assemblies may be one of the most important causes of Alzheimer's disease. Passive immunization of anti-amyloid-beta antibodies can reduce amyloid-beta burden and improved memory performance in various Alzheimer's disease animal models or patients. Screening humanized antibodies from a human Fab phage display library is an effective and quick method to obtain beta-amyloid oligomers. Thus, a recent study published in the Neural Regeneration Research (Vol. 8, No. 33, 2013)...

Boosting A Malaria Vaccine
2013-12-27 12:34:32

Brett Smith for redOrbit.com - Your Universe Online According to a study published in the journal PLOS Pathogens on Thursday, a prominent malaria vaccine could be drastically improved by utilizing the right mix of proteins taken from the surface of the virus. The study researchers focused on the virus’ AMA1 protein, which the human body recognizes and uses to stimulate an immune response. However, the protein exists in multiple strains – causing problems for researchers looking to...

2013-12-19 23:23:22

St. George’s to Utilize DNA2.0’s GeneGPS® Expression Technology to Increase Protein Expression in Tobacco for the Production of Therapeutic Antibodies Menlo Park, Calif. (PRWEB) December 19, 2013 DNA2.0 has entered into a research collaboration with the Infection and Immunity Research Centre at St. George’s, University of London, to support the development of plant-based biopharmaceuticals. Professor Julian Ma and his research group at St. George’s have made significant...

2013-12-19 20:21:42

Transaction Provides Sorrento with Comprehensive Antibody Drug Conjugate Technology Platform SAN DIEGO, Dec. 19, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) announced today that it has completed its acquisition of Concortis Biosystems, Corp., providing Sorrento with a comprehensive technology platform to create a new generation of homogenous antibody drug conjugates (ADCs) with site-specific toxin conjugation and consistent drug-antibody ratios. With the...

2013-12-19 10:35:03

A newly identified immune protein influences each person's response to vaccines and risk for autoimmune diseases like lupus and multiple sclerosis, according to a study published today by researchers from the School of Medicine at the University of Alabama at Birmingham in the journal Science Translational Medicine. The protein, called a receptor and part of signaling pathways, also provides a new target for personalized therapies for patients with autoimmune diseases. The research team...

Potential Malaria Vaccine Blocks Parasite
2013-12-17 09:59:38

Rebekah Eliason for redOrbit.com – Your Universe Online There is new hope for the billions of people exposed to malaria each year. Scientists from Nanyang Technological University (NTU) in Singapore have discovered a way to block the malaria parasite from invading the blood cells. Using this new research, scientists from NTU are seeking to team up with the vaccine development industry to produce a malaria vaccine. If the process is accelerated by these companies, lead scientist...

2013-12-17 08:29:17

SAN DIEGO, Dec. 17, 2013 /PRNewswire/ -- AnaptysBio, Inc., a privately-held therapeutic antibody company today announced the initiation of an antibody development program with Momenta Pharmaceuticals, Inc. focused on the development of novel antibodies against a therapeutically relevant target. Under this agreement, Momenta will pay an upfront fee to AnaptysBio in exchange for an option to acquire antibodies generated by AnaptysBio using its SHM-XEL platform against a specific...

2013-12-17 04:20:55

BREDA, The Netherlands and GHENT, Belgium, December 17, 2013 /PRNewswire/ -- Dose confirmed for Phase Ib safety and efficacy expansion study arGEN-X announces that the dose-escalation part of a Phase Ib study with its lead antibody ARGX-110 has met its translational development goals: all pre-specified biological activity measures (e.g. target engagement, effector functions, immune-modulation) were met. The study also showed that ARGX-110 has a favourable...

2013-12-16 04:21:30

LONDON and BOSTON, December 16, 2013 /PRNewswire/ -- Biased Agonist Antibodies Generated To G Protein-Coupled Receptor Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces the publication of a new scientific paper describing the use of StaR(R) proteins (thermostabilised G protein-coupled receptors, GPCRs) as antigens for antibody drug discovery. StaR proteins based on the beta1-adrenergic (beta1AR) receptor were...